The Novartis Biome, whose first digital health innovation lab is based in San Francisco, has been co-founded by its head Mohanad Fors, head of open innovation Shwen Gwee and head of innovation and ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali. The Swiss pharmaceutical ...

Exactly three years after an initial FDA green light for the third-line treatment of leukemia, Novartis’ Scemblix has won an accelerated approval to treat newly diagnosed patients. Tuesday ...

LONDON — It hasn’t even been a year since Pfizer closed its $43 billion acquisition of Seagen — one of the biggest biopharma deals in years — but David Epstein, who was CEO of Seagen, is back.

A suit against Novartis and Vitaris by Henrietta Lacks’ estate hinges on questions about the morality and legality of using ...

Oct 16 (Reuters) - Novartis (NOVN.S), opens new tab has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by blocking regulators from ...

Novartis has terminated a phase 2 trial of its SMURF1 inhibitor LTP001 in idiopathic pulmonary fibrosis (IPF) but will continue to advance the candidate in another indication. The Swiss drugmaker ...

While the diagnostics are often used in tandem with therapeutics, Novartis said that it would ... specialises in medical imaging technologies, lab diagnostics, and other ancillary services like ...

Novartis NOVN-1.67%decrease; red down pointing triangle raised its guidance for the third time this year after higher third-quarter results topped expectations, boosted by revenue from its ...

As expected, Novartis’ radioligand therapy Pluvicto crossed the blockbuster sales threshold with one quarter still left of 2024. But some may not be satisfied with the prostate cancer med’s ...

The previous update I wrote on Novartis was the Q2 earnings preview and I want to note that while my estimates on some of the key growth products were off, the general direction of my prediction ...

Truist highlights Novartis' strong balance sheet, which enables further bolt-on deals and share buybacks. Recent transactions primarily involve deals in the sub-$1 billion range, along with a few ...